聚乙二醇化脂质体阿霉素和环磷酰胺±曲妥珠单抗新辅助治疗后序贯多西他赛用于局部晚期乳腺癌的II期研究 - Suppr

Suppr

超能文献

Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.

作者信息

Tuxen Malgorzata K, Cold Soeren, Tange Ulla B, Balslev Eva, Nielsen Dorte L

机构信息

Department of Oncology, Herlev University Hospital , Herlev , Denmark.

出版信息

Acta Oncol. 2014 Oct;53(10):1440-5. doi: 10.3109/0284186X.2014.921727. Epub 2014 Jul 3.

DOI:10.3109/0284186X.2014.921727

PMID:24991893

Abstract

摘要

相似文献

Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.

Acta Oncol. 2014 Oct;53(10):1440-5. doi: 10.3109/0284186X.2014.921727. Epub 2014 Jul 3.

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.

Breast. 2013 Dec;22(6):1101-7. doi: 10.1016/j.breast.2013.09.001. Epub 2013 Sep 26.

Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.

J Clin Oncol. 2007 Apr 1;25(10):1232-8. doi: 10.1200/JCO.2005.05.3306. Epub 2007 Feb 12.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.

Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.

Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16.

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22.

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.

Eur J Cancer. 2011 Sep;47(14):2091-8. doi: 10.1016/j.ejca.2011.05.005. Epub 2011 Jun 12.

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.

J Clin Oncol. 2010 Apr 20;28(12):2015-23. doi: 10.1200/JCO.2009.23.8303. Epub 2010 Mar 22.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Isr Med Assoc J. 2006 Jun;8(6):416-21.

引用本文的文献

Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.

Chin J Cancer Res. 2024 Feb 29;36(1):55-65. doi: 10.21147/j.issn.1000-9604.2024.01.06.

Liposomes for Cancer Theranostics.

Pharmaceutics. 2023 Oct 11;15(10):2448. doi: 10.3390/pharmaceutics15102448.

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.

Front Oncol. 2022 Jul 8;12:909426. doi: 10.3389/fonc.2022.909426. eCollection 2022.

Pegylated Liposomal Doxorubicin (Caelyx) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.

Curr Oncol. 2021 Dec 7;28(6):5167-5178. doi: 10.3390/curroncol28060433.

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.

BMC Cancer. 2021 Dec 6;21(1):1301. doi: 10.1186/s12885-021-09050-6.

The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan.

Biochem Res Int. 2020 Apr 28;2020:5729389. doi: 10.1155/2020/5729389. eCollection 2020.

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.

Breast Cancer (Dove Med Press). 2018 Dec 27;11:29-42. doi: 10.2147/BCTT.S179750. eCollection 2019.

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis.

Ther Clin Risk Manag. 2018 Sep 26;14:1789-1797. doi: 10.2147/TCRM.S176214. eCollection 2018.

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer.

Breast Cancer (Dove Med Press). 2018 Sep 11;10:131-141. doi: 10.2147/BCTT.S170239. eCollection 2018.

Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials.

J Cancer. 2018 Aug 6;9(17):3168-3176. doi: 10.7150/jca.24701. eCollection 2018.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验